Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curodont D'Senz is a desensitizing tooth gel that uses patented Oligo-Peptide 103 technology to treat dentine hypersensitivity. The product forms a stable, protective barrier on exposed dentinal tubules, effectively occluding open tubules within 2 minutes to inhibit pain induced by thermal and contact stimuli. This biomimetic, mineral-rich peptide layer creates a barrier against the transmission of external stimuli to nerve endings, providing effective desensitization. Clinical studies have shown that Curodont D'Senz provides faster relief from sensitivity than conventional anti-sensitivity toothpastes, with 80% of patients reporting relief after 7 days and effects lasting up to 90 days even after discontinuation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Curodont D'Senz.